Reuters -- Nycomed hopes to pick a U.S. licensing partner for Daxas, its "smoker's lung" drug, by the end of June and ultimately aims for a stock market listing, the privately held Swiss drugmaker said on Tuesday.
Reuters -- Nycomed hopes to pick a U.S. licensing partner for Daxas, its "smoker's lung" drug, by the end of June and ultimately aims for a stock market listing, the privately held Swiss drugmaker said on Tuesday.
